Tebipenem clinical trials
Also written SPR994 and TBPM-PI-HBr.
How each study uses tebipenem is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 17 Jun 2026 · UTEBZI · NDA 215960 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 1
Studies
Open first, then newest update. How each study uses tebipenem is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)CompletedPhase 3Spero TherapeuticsNCT06059846Written as TBP-PI-HBr
- A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy ParticipantsCompletedPhase 1Spero TherapeuticsNCT06727136Written as TBP-PI-HBr
- A Study to Compare Two Bioanalytical Assays for TebipenemCompletedPhase 1Spero TherapeuticsNCT05856747Written as TBP-PI-HBr
- Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo MicrodialysisCompletedPhase 1Hartford HospitalNCT04919954Written as Tebipenem Pivoxil Hydrobromide
- Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)CompletedPhase 3Spero TherapeuticsNCT03788967Written as TBPM-PI-HBr
- Effect of Tebipenem on Normal Human Intestinal MicrobiotaCompletedPhase 1Spero TherapeuticsNCT04376554Written as TBPM-PI-HBr
- Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking VolunteersCompletedPhase 1Spero TherapeuticsNCT04710407Written as TBPM-PI-HBr
- Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal FunctionCompletedPhase 1Spero TherapeuticsNCT04178577Written as Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
- Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 1Spero TherapeuticsNCT04625855Written as TBPM-PI-HBr
- Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult SubjectsCompletedPhase 1Spero TherapeuticsNCT04368585Written as Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
- Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult SubjectsCompletedPhase 1Spero TherapeuticsNCT04421885Written as Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference
- A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy SubjectsCompletedPhase 1Spero TherapeuticsNCT04238195Written as Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo
- Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994CompletedPhase 1Spero TherapeuticsNCT03395249Written as SPR994
Codes
What other systems call tebipenem · ClinicalTrials.gg INT004773
- MeSH (NLM) C500135tebipenemOne source NLM
- UNII (FDA) Q2TWQ1I31UTEBIPENEMConfirmed FDA, NLM, Wikidata
- Wikidata Q27286930tebipenemConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C219319TebipenemOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C500135 | tebipenem | One source NLM |
| UNII (FDA) | Q2TWQ1I31U | TEBIPENEM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27286930 | tebipenem | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C219319 | Tebipenem | One source FDA |
Also registered as tebipenem pivoxil hydrobromide (UNII NT65DX774J).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.